Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3.

Having a body mass index above or equal to 30 kg/m(2) in conjunction with chronic hepatitis C virus infection is associated with non-responsiveness to treatment with interferon and ribavirin, but details regarding the mechanisms whereby obesity reduces the efficacy of therapy remain unclear.This stu...

Full description

Bibliographic Details
Main Authors:	Åsa Alsiö, Karolina Rembeck, Galia Askarieh, Peer Brehm Christensen, Martti Färkkilä, Nina Langeland, Mads Rauning Buhl, Court Pedersen, Kristine Mørch, Bart L Haagmans, Salmir Nasic, Johan Westin, Kristoffer Hellstrand, Gunnar Norkrans, Martin Lagging
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2012-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3360051?pdf=render

Internet

http://europepmc.org/articles/PMC3360051?pdf=render

Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3.

Internet

Similar Items